405 related articles for article (PubMed ID: 21467163)
1. Cytotoxic T-lymphocyte-associated antigen-4.
Salama AK; Hodi FS
Clin Cancer Res; 2011 Jul; 17(14):4622-8. PubMed ID: 21467163
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
3. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
6. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
8. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
10. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
Keilholz U
J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
[TBL] [Abstract][Full Text] [Related]
12. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E; Hodi FS
J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
15. Targeting lymphocyte co-stimulation: from bench to bedside.
Felix NJ; Suri A; Salter-Cid L; Nadler SG; Gujrathi S; Corbo M; Aranda R
Autoimmunity; 2010 Nov; 43(7):514-25. PubMed ID: 20429850
[TBL] [Abstract][Full Text] [Related]
16. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
19. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
